BioBrief’s special week-ahead edition previews the key biotech and biopharma events to watch for the week of May 18, with pulmonary data, oncology positioning, and FDA regulatory updates in focus.

In today’s BioBrief:

• United Therapeutics / ralinepag — Phase 3 ADVANCE OUTCOMES data in pulmonary arterial hypertension showed a 55 percent reduction in clinical worsening risk, setting up a planned NDA filing in the second half of 2026.
• ASCO abstracts — Regular ASCO abstracts are scheduled for release on Thursday, May 21, creating an important oncology positioning event ahead of the full meeting.
• Enhertu — Daiichi Sankyo and AstraZeneca enter the week with two new FDA approvals for Enhertu in HER2-positive early-stage breast cancer.
• ATS respiratory watch ...